9 recruiting, 2 not yet recruiting, 1 completed, 1 enrolling by invitation. 8 Phase 2, 4 Not applicable, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 6, Not yet recruiting 2 |
| Not applicable | 4 | Recruiting 2, Completed 1, Enrolling by invitation 1 |
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
Follow Head and Neck Cancer Squamous Cell Carcinoma: new trials by email Literature Review of Head and Neck Cancer Squamous Cell Carcinoma trials Research Report on Head and Neck Cancer Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial Comparing an Antibody (INCA33890) Versus Pembrolizumab for Squamous Cell Carcinoma of the Head and Neck. INCA33890, Pembrolizumab - Head and Neck Cancer Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Groupe Oncologie Radiotherapie Tete et Cou | 78 | 2027-02-01 | 2026-10-22 |
| Immunotherapy and Nodal-Sparing Irradiation for T-Cell Induction and Unmasking of Tumor Antigenicity in the Microenvironment for Head and Neck Cancer Pembrolizumab, Radiotherapy, ENI - Head and Neck Cancer Squamous Cell Carcinoma | Phase 2 | Recruiting | Medical College of Wisconsin | 20 | 2026-10-08 | 2026-10-19 |
| PDT For Induction Therapy For Head And Neck Cancer Toripalimab-tpzi, Cisplatin, Docetaxel - Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma | Phase 2 | Recruiting | Massachusetts General Hospital | 26 | 2026-03-09 | 2026-10-19 |
| A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer cisplatin+ nab-paclitaxel +adebrelimab + imaxitinib - Head and Neck Cancer Squamous Cell Carcinoma | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 76 | 2026-01-01 | 2026-03-09 |
| Stereotactic Post-operative Radiotherapy for Intraparotid Metastatic Cutaneous Squamous Cell Carcinoma SBRT, Standard Radiation - Cutaneous, Head and Neck Cancer Squamous Cell Carcinoma | Not applicable | Recruiting | David Palma | 90 | 2025-10-21 | 2026-01-13 |
| Ozone Therapy for Oral Mucositis in Patients Receiving Head and Neck Cancer Radio- and Chemotherapy Ozone Therapy (In-Office and Home-Based Treatment) - Oral Mucositis, Oral Stomatitis | Not applicable | Completed | University of Pavia | 58 | 2025-10-01 | 2025-11-25 |
| Improved Oral Health in Head and Neck Cancer Survivors Oral health support - Head and Neck Cancer Squamous Cell Carcinoma, Head and Neck Cancer | Not applicable | Recruiting | Uppsala University | 300 | 2025-09-25 | 2026-09-03 |
| Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base Neoadjuvant chemoimmunotherapy, Tislelizumab Nab paclitaxel - Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 24 | 2025-09-20 | 2025-08-28 |
| Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer VS-101, Cisplatin, Radiation - Head and Neck Cancer Squamous Cell Carcinoma | Phase 2 | Recruiting | VSPharmTech Co.,Ltd. | 30 | 2025-06-11 | 2026-09-02 |
| A Study of SH009 Injection in Patients With Advanced Solid Tumors. SH009 - Liver Cancer (Locally Advanced or Metastatic), Lung Cancer (NSCLC) | Phase 1 | Recruiting | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 150 | 2025-05-16 | 2026-02-05 |
| Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC combination of Surufatinib and Envolizumab - Head and Neck Cancer, Head and Neck Cancer Squamous Cell Carcinoma | Phase 2 | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 24 | 2024-12-30 | 2025-03-14 |
| Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCC Trilaciclib + Cisplatin - Head and Neck Cancer Squamous Cell Carcinoma | Phase 2 | Recruiting | Hunan Cancer Hospital | 30 | 2024-12-30 | 2024-12-31 |
| Hypofractionated Radiotherapy for HNSCC in Elderly Patients Hypofractionated Radiation Therapy - Head and Neck Cancer Squamous Cell Carcinoma, ELDERLY PEOPLE | Not applicable | Enrolling by invitation | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 51 | 2024-01-01 | 2025-01-10 |
| Study of ADCT-301 in Patients With Selected Advanced Solid Tumors ADCT-301, Pembrolizumab - Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer | Phase 1 | Terminated | ADC Therapeutics S.A. | 78 | 2018-11-09 | 2024-06-13 |
Head and Neck Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (2) · Esophageal Neoplasms (2) · Stomach Neoplasms (2) · Agnosia (1) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Colonic Neoplasms (1) · Fallopian Tube Neoplasms (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1)
Neoplasms (7) · Neoplasms by Site (7) · Breast Diseases (2) · Bronchial Neoplasms (2) · Carcinoma (2) · Carcinoma, Bronchogenic (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Esophageal Diseases (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Head and Neck Neoplasms (2) · Lung Diseases (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2)
Cisplatin (4) · pembrolizumab (3) · Surgical Procedures, Operative (2) · Docetaxel (1) · Radiation (1) · Radiotherapy (1) · trilaciclib (1)
ADC Therapeutics S.A. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · David Palma (1) · Groupe Oncologie Radiotherapie Tete et Cou (1) · Hunan Cancer Hospital (1) · Massachusetts General Hospital (1) · Medical College of Wisconsin (1) · Nanjing Sanhome Pharmaceutical, Co., Ltd. (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1) · Sun Yat-sen University (1) · University of Pavia (1) · Uppsala University (1) · VSPharmTech Co.,Ltd. (1)
China (6) · United States (4) · Belgium (1) · Canada (1) · Italy (1) · Sweden (1) · United Kingdom (1)
Andrea Scribante, Associate Professor (1) · Musaddiq Awan, MD (1) · Thomas Roberts, MD, MBA (1) · Ye Y Zhang (1) · Yujie Liang (1)
PMID 15825201, PMID 18486742, PMID 18784101, PMID 23129742, PMID 27718784, PMID 30509740, PMID 31679945, PMID 33243985, PMID 34473219, PMID 35585121, PMID 35766967, PMID 37395170, PMID 37991778, PMID 38110599, PMID 38467604, PMID 42717322
2019 (1), 2023 (1)